Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro
J Redondo, P Sarkar, K Kemp, PF Virgo… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Autologous bone-marrow-derived cells are currently employed in clinical
studies of cell-based therapy in multiple sclerosis (MS) although the bone marrow …
studies of cell-based therapy in multiple sclerosis (MS) although the bone marrow …
[HTML][HTML] Percutaneous endoscopic gastrostomy tube insertion in neurodegenerative disease: a retrospective study and literature review
P Sarkar, A Cole, NJ Scolding, CM Rice - Clinical endoscopy, 2017 - ncbi.nlm.nih.gov
Methods A retrospective case note review of patients referred for PEG insertion by neurologists
in a single neuroscience center was conducted according to a pre-determined set of …
in a single neuroscience center was conducted according to a pre-determined set of …
Dysregulation of mesenchymal stromal cell antioxidant responses in progressive multiple sclerosis
J Redondo, P Sarkar, K Kemp… - Stem Cells …, 2018 - academic.oup.com
The potential of autologous cell-based therapies including those using multipotent
mesenchymal stromal cells (MSCs) is being investigated for multiple sclerosis (MS) and other …
mesenchymal stromal cells (MSCs) is being investigated for multiple sclerosis (MS) and other …
[HTML][HTML] Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial
…, MG Guttridge, G Miflin, S Blackmore, P Sarkar… - Trials, 2015 - Springer
Background We have recently completed an evaluation of the safety and feasibility of intravenous
delivery of autologous bone marrow in patients with progressive multiple sclerosis (MS…
delivery of autologous bone marrow in patients with progressive multiple sclerosis (MS…
[HTML][HTML] Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis
P Sarkar, J Redondo, K Kemp, M Ginty, A Wilkins… - Cytotherapy, 2018 - Elsevier
Background Clinical trials using ex vivo expansion of autologous mesenchymal stromal
cells (MSCs) are in progress for several neurological diseases including multiple sclerosis (MS). …
cells (MSCs) are in progress for several neurological diseases including multiple sclerosis (MS). …
Cell therapy for multiple sclerosis
P Sarkar, CM Rice, NJ Scolding - CNS drugs, 2017 - Springer
Cell therapy is considered a promising potential treatment for multiple sclerosis, perhaps
particularly for the progressive form of the disease for which there are currently no useful …
particularly for the progressive form of the disease for which there are currently no useful …
Peer mentoring for core medical trainees: uptake and impact
J Webb, A Brightwell, P Sarkar, R Rabbie… - Postgraduate …, 2015 - academic.oup.com
Objective To assess the uptake and impact of a peer mentoring scheme for core medical
trainees on both mentors and mentees. Method All second year core medical trainees in the …
trainees on both mentors and mentees. Method All second year core medical trainees in the …
Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II)
…, NM Kane, MG Guttridge, J Redondo, P Sarkar… - BMJ open, 2015 - bmjopen.bmj.com
Introduction The ‘Study of Intravenous Autologous Marrow in Multiple Sclerosis (SIAMMS)’
trial was a safety and feasibility study which examined the effect of intravenous infusion of …
trial was a safety and feasibility study which examined the effect of intravenous infusion of …
Transverse myelitis caused by hepatitis E: previously undescribed in adults
P Sarkar, C Morgan, S Ijaz - Case Reports, 2015 - casereports.bmj.com
We report the case of a 62-year-old Caucasian woman who was admitted with urinary
retention and lower limb paraesthesia following a week9s prodromal illness of headache and …
retention and lower limb paraesthesia following a week9s prodromal illness of headache and …
Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated …
P Sarkar, J Redondo, K Hares, S Bailey… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Background: Cell-based therapies for multiple sclerosis (MS), including those employing
autologous bone marrow-derived mesenchymal stromal cells (MSC) are being examined in …
autologous bone marrow-derived mesenchymal stromal cells (MSC) are being examined in …